



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231
WWW.USPTO.GOV

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09 689,621	10 13 2000	Kent R. Van Kampen	7203 01	8418

25934 7590 03.11.2003

DORSEY & WHITNEY LLP
INTELLECTUAL PROPERTY DEPARTMENT
801 GRAND, SUITE 3900
DES MOINES, IA 50309

EXAMINER

LANKFORD JR, LEON B

ART UNIT	PAPER NUMBER
----------	--------------

1651

DATE MAILED 03 11 2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/689,621

Applicant(s)

VAN KAMPEN ET AL.

Examiner

L Blaine Lankford

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 31 January 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-36 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1-31-03 has been entered.

Applicant's arguments filed 1-31-03 have been fully considered but they are not persuasive. The 35 U.S.C. 103(a) rejection is maintained for the reasons of record.

In response to applicant's arguments: The claimed invention has been considered as a whole. The references have been considered as a whole. No impermissible hindsight has been used- it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). A reasonable expectation of success has been established in the previous office actions.

Applicant argues that although the prior art teaches that the claimed killed bacteria is a known effective immunopotentiator there is no evidence that this fact would suggest an effective treatment for a particular disease. Applicant's claims are not drawn to specific diseases but classes thereof, nor do the claims require a specific level of treatment. Applicant's arguments have been considered however a showing to overcome a prima facie case of obviousness must be clear and convincing(*In re Lohr et al.* 137 USPQ 548) as well as commensurate in scope with the claimed subject matter (*In re Lindner* 173 USPQ 356; *In re Hyson*, 172 USPQ 399 and *In re Boesch et al.*, 205 USPQ 215 (CCPA 1980). The prior art's teaching of immunostimulation is sufficient to suggest that administering the claim designated product to a patient suffering from a dermal tumor or respiratory tract infection will treat the disease in some degree given the breadth of effective treatments taught in the art. There is a reasonable expectation that stimulating the immune system will aid a body in its defense against a tumor or infection. Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made especially in the absence of evidence to the contrary.

Applicant would appear to allege criticality with regard to the sterilization method of the bacteria used in the claimed process. However, there is not clear and convincing evidence of criticality now of record. Also, the prior art only suggests that inactivation is required and terminal sterilization is a notoriously old and well known method of inactivation. Slight variations in results are expected in

microbiological/biochemical processes, however applicant has not argued nor demonstrated that the sterilization procedure effects the pharmaceutically effectiveness of the bacteria. Any differences would need to rise to the level of unexpected or unobvious.

Applicant has requested an interview, and if such is still desired, is invited to call the undersigned examiner.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-36 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Adlam et al and Evans et al and Fujiwara et al and Howard et al and Megid et al and Neifeld et al (all cited by applicant).

Adlam and Evans and Fujiwara and Howard and Megid and Neifeld all teach the administration of *C parvum* or *P acnes* to a patient to cause an antineoplastic and/or antiviral effect. In fact, it is notoriously old and well known in the art that the administration of *C parvum* or *P acnes* (or toxins or cell wall fragments thereof) to a patient has an antineoplastic and/or antiviral effect. Applicant clearly acknowledges this in the first few pages of the instant specification. What is not taught is the specific use of the bacteria for the tumor claimed in claim 1 or the specific use of the bacteria to treat viral lung infections in humans. However, given the breadth of the prior art, i.e. the non-specific immunological benefits (for a huge variety of tumors and viral infections) that the art recognizes when the bacteria is administered to humans or other animals and the fact that the large number of animal studies correlate well to human usage, it would have been obvious at the time the invention was made to treat dermal tumors and viral lung infections by administering the bacteria to a patient in need thereof. The huge breadth of teachings in the art give the skilled artisan a reasonable expectation of success to treat neoplastic or viral maladies.

As the references clearly indicate that the various proportions and amounts of the ingredients used in the claimed methods (formulations, etc) are result effective

Art Unit: 1651


variables, they would be routinely optimized by one of ordinary skill in the art in practicing the invention disclosed by those references.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made especially in the absence of evidence to the contrary.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to L Blaine Lankford whose telephone number is 308-2455. The examiner can normally be reached on Mon-Thu 7:30-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-0196.


L. Blaine Lankford
Primary Examiner
Art Unit 1651

LBL
March 7, 2003